Close Menu

Webinar/Video Library

June 03, 2019
Sponsored by
SeraCare

A Non-Small Cell Lung Cancer Reference Material

Partner Webinar

About 10-50 percent of Non-small-cell lung cancers have one of several activating EGFR driver mutations that have been clinically validated as therapeutic biomarkers for anti-EGFR drugs. Identifying these driver mutations through liquid biopsies is a promising alternative to traditional biopsies; however, the precision of mutation analysis for some of these targets remains a challenge.

Watch this video to see how Seracare developed a platform of single and low complexity, patient-like circulating tumor DNA (ctDNA) reference standards that can be used in NGS and real-time PCR assays.

Sponsored by
Genome Webinar

Clinical Microbiologist,
Ikazia Hospital

This webinar discusses the implementation of a rapid 24/7 PCR service in a small urban hospital setting.

Modern PCR technologies are changing the workflow of medical microbiology laboratories, making it possible to get molecular test results within an hour instead of days to weeks. Smaller and cheaper analyzers also make multiplex PCR techniques possible for smaller laboratories without a molecular department.

This webinar illustrates the impact of new PCR technologies in the hospital setting. Our speaker, Michiel van Rijn, is a clinical microbiologist and head of the Department of Clinical Microbiology at the Ikazia Hospital in Rotterdam. Although the Ikazia hospital is one of the smaller hospitals in Rotterdam (360 beds), it has offered a "24/7" PCR service to its medical staff for 10 years, starting with molecular screening for methicillin-resistant Staphylococcus aureus in 2009. The hospital has expanded its portfolio in the last decade, and most recently rolled out multiplex syndromic testing in 2018.

In this webinar, Dr. van Rijn speaks about the implementation of a rapid 24/7 PCR service in his hospital and the effects of this service on patient outcomes and clinical decision making strategies. In particular, he shares his experiences with QIAstat-Dx syndromic testing and his expectation of further use of this technique in the future.

QIAstat-Dx is coming soon. Currently available as DiagCORE. DiagCORE is not available in all countries.

Sponsored by
Genome Webinar

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

LRTseq technologies, such as Pacific Biosciences’ Iso-Seq and Oxford Nanopore’s cDNA sequencing, have the power to provide rapid high-quality de novo transcriptome annotations. However, standard cDNA library preparation methods for LRTseq capture a significant amount of degraded RNA and are often overpopulated with highly expressed genes.

Degraded RNA reduces the efficiency of sequencing and introduces uncertainty with respect to predicted transcription start sites. Highly expressed genes can dominate LRTseq data, resulting in a loss of coverage for lower expressed genes. This typically results in missing genes and alternative transcripts in the final genome annotation.

In this webinar, Richard Kuo of the Roslin Institute will discuss how his team addressed RNA degradation by using Lexogen’s cap-specific TeloPrime method to prepare full-length cDNA libraries. To reduce overabundant genes, Kuo and colleagues experimented with two methods of cDNA normalization.

He will present his team’s results using these novel methods of cDNA preparation for Iso-Seq sequencing and will also cover some basics of LRTseq and analysis pipelines for Iso-Seq (from raw data to transcriptome annotation). 

Sponsored by
April 26, 2019
Sponsored by
Oracle Health Sciences

Run Healthcare Workloads on Oracle HIPAA-Attested Cloud Services

Partner Webinar

Want to increase flexibility and agility while reducing costs by running healthcare workloads in the Cloud, but need assurance of HIPAA compliance for PHI data? Oracle successfully concluded another series of HIPAA attestations for Platform as a Service (PaaS) and Infrastructure as a Service (IaaS), adding to existing HIPAA-attested Software as a Service (SaaS) and SOC1/2 attestations for Cloud Services. We will discuss the results of the latest 3rd party attestations, healthcare use cases relevant for Oracle Cloud, and illustrations of successful healthcare customers.

During this webinar you will learn:
- New and existing HIPAA and SOC- attested Oracle Cloud Services 
- Oracle Cloud options that give you complete freedom to choose
- Healthcare use cases that are popular choices for moving to Oracle Cloud
- How other Healthcare organizations are succeeding with Oracle Cloud

Sponsored by
Genome Webinar

This webinar provides a wide-ranging overview of the promise for metabolomics in studying human health and disease, as well as its potential for integration with other -omics disciplines.

Our speaker, Dr. Jerzy Adamski of the Helmholtz Center Munich, reviews current approaches in targeted and non-targeted metabolomics, highlighting differences in methodology, coverage, advantages, and disadvantages of either approach. 

This webinar puts a special emphasis on the universal applications of broad targeted metabolomics assays, which have shown promise in delineating factors contributing to the clinical phenotype, including intrinsic and environment-related processes. Dr. Adamski also touchs upon the benefits of calculating metabolite sums and ratios along the most important metabolic pathways.

The acknowledgement of the importance of host-microbiota interaction warrants a look at how metabolomics can help this rather young research field move beyond associations between disease risk and microbial genetics, and towards a more thorough functional understanding of the involved processes. For this purpose, Dr. Adamski highlights selected metabolic pathways that are known to be associated with gut microbiota and affect health via direct metabolic and immune-related effects.

Finally, Dr. Adamski discusses how metabolomics can integrate with other -omics technologies, providing examples of how metabolomics has enhanced genome-wide association studies, among others.

Sponsored by
Genome Webinar

In 2016, the Association for Molecular Pathology (AMP), in partnership with the College of American Pathologists (CAP) and American College of Molecular Genetics (ACMG), launched a set of guidelines meant to set industry standards for reporting of molecular diagnostic test results in oncology, using a tier-based system and defined levels of evidence. Upon the release of these guidelines, several laboratories and molecular diagnostic decision-support companies incorporated them into their reporting to give pathologists and treating oncologists a more consistent report format that clearly conveys the level of importance and evidence for each variant, enabling them to provide the most relevant treatment options for oncology patients.

In this webinar, Dr. Timothy Cannon, Medical Director for Gastrointestinal Cancers at Inova Medical Group, Dr. Marilyn Li, Vice Chief of the Division of Genomic Diagnostics at Children’s Hospital of Philadelphia, and Dr. Sheryl Elkin, CSO of N-of-One, a Qiagen company, discuss adoption of the guidelines in the field to date, what’s working, and any new challenges/opportunities that have come from the initial launch.

Attendees can expect to learn about some of the complexities that exist in incorporating the AMP guidelines into treatment strategies, as well as what might be on the horizon in industry standardization for levels of evidence.  

Sponsored by
Genome Webinar

This webinar provides an overview of current biomarker strategies for guiding the use of combination checkpoint immunotherapies in blood cancers.

Checkpoint immunotherapy has proven to be a powerful therapeutic against a variety of cancers, yet due to response rates that range between 20 percent and 40 percent, researchers and drug developers continue to seek ways to indicate response or non-response as early as possible. A particular area of focus is biomarkers that can assess the status of the pre-therapy tumor microenvironment in order to predict response.

Our speaker, Naval Daver of MD Anderson Cancer Center, discusses advanced immune-based approaches in acute myeloid leukemia that combine chemotherapy with checkpoint therapy, along with the relevant biomarker strategies associated with each.

Dr. Daver also describes a study based on a single-cell cytokine analysis system and Polyfunctional Strength Index (PSI) from Isoplexis that demonstrated that certain cytokine potency contributors, in particular from stimulatory cytokines, correlate with overall survival.

In addition, Jon Chen of Isoplexis shares several case studies using tumor-infiltrating lymphocytes in combination checkpoint immunotherapy that correlate polyfunction to outcome.

*Due to the location of our speakers, this webinar is pre-recorded.

Sponsored by
Genome Webinar

This webinar reviews a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples. 

Genomic analysis has driven major advances in leukemia, where the spectrum of driver mutations provides a much more rigorous classification of disease subtypes, with a correspondingly more robust prognostic power, than previous histological characterization.

In this webinar, Dr. James Broach, Director of the Penn State Institute for Personalized Medicine, discusses a study that indicates there are far more structural variants in leukemia than previously thought.

Dr. Broach and his team combined whole-genome sequencing and optical genome mapping to a number of adult and pediatric leukemia samples. The method identified 97 percent of the structural variants previously reported by karyotype analysis of these samples, as well as an additional fivefold more such somatic rearrangements. 

The method identified on average tens of previously unrecognizable inversions and duplications and hundreds of previously unrecognizable insertions and deletions. These structural variants affected a number of leukemia-associated genes as well as cancer driver genes not previously associated with leukemia and genes not previously associated with cancer. Analysis indicates that the status of several of the recurrently mutated genes identified in this study significantly affect survival of AML patients.

Dr. Broach discusses the implications of the findings, which suggest that current genomic analysis methods fail to identify a majority of structural variants in leukemia samples — an omission that may hamper diagnostic and prognostic efforts.

Sponsored by
Genome Webinar

 

 

This webinar will present the utility of a personalized in silico analytical approach for the routine clinical diagnosis of channelopathies and cardiomyopathies.

The advent of next-generation sequencing (NGS) has greatly improved the ability to rapidly assess many genes at the same time, but the analysis and interpretation of complex genomic variants still remains a challenge. In order for NGS to find use in routine diagnostics, clinical laboratories must be able to overcome this complexity and enable better outcomes for patients.

Dr. Alexandre Janin, member of the molecular cardiogenetic lab at Hospices Civils de Lyon in France, has solved this complexity and successfully characterized difficult variants by adopting the Sophia Platform.

Dr. Janin will discuss how the platform:

  • Enables fast and comprehensive analysis;
  • Detects copy number variations quickly and efficiently;
  • Facilitates variant interpretation by sharing knowledge among members of the national network for Hereditary Cardiac Diseases (Cardiogen)

Dr. Janin will be joined by Dr. Audrey Coiffic, Clinical Application Product Manager at Sophia Genetics, who will discuss the most recent developments in targeted solutions for the advanced detection of inherited cardiac diseases.

Sponsored by
Genome Webinar

Research Associate, Institute of Medical Genetics, Cardiff University

Senior Software Developer and Analyst, Institute of Medical Genetics, Cardiff University, Cardiff, UK

The Human Gene Mutation Database (HGMD) is a manually curated, comprehensive collection of disease-causing, germline mutations. Since 1996, a team of experts has manually catalogued over a quarter of a million mutations for the database.  

This talk will feature a retrospective view of HGMD, how it has grown over time, and the research that it has enabled. In particular, our speakers will talk about how HGMD has helped move precision medicine forward by providing translational research and diagnostic applications with the most comprehensive survey of literature on genetic mutations responsible for human inherited diseases, supporting standardized interpretation for germline diseases. 

Sponsored by
Genome Webinar

Senior NGS Specialist, UCL Genomics

Product Manager, Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. Traditionally, prior to sequencing, next-generation sequencing library technicians and automation strategies have had to undertake numerous steps to quantify and normalize NGS libraries.

In this webinar, Tony Brooks, Senior NGS Specialist at University College London Genomics, discusses how his core facility implemented the Swift Normalase Kit, a novel enzymatic library normalization product that streamlines the cumbersome steps following NGS library preparation. 

Compared to conventional normalization, Swift Normalase saves sequencing costs by reducing read depth variation within a pool from a typical CV of 10-25% to a CV <10%. With a simple bead-free, quantification-free, two-step workflow, Normalase enables bulk processing of samples and expedites library pooling and loading to save time and cost.

Tony shares how his lab used the Swift Normalase kit for RNAseq library normalization to improve his facility's sequencing workflow and to reduce cost.

Sponsored by
March 26, 2019
Sponsored by
PerkinElmer

Advancing Agricultural Genomics with Low-Cost NGS Genotyping

Genome Webinar

Director and Founder, Texas A&M AgriLife Genomics and Bioinformatics Service

This webinar addresses the current status and future directions for massively high-throughput genomics for plant and animal breeding and research.

A major drawback to sequencing-based agriculture studies has been the cost. Arrays and reduced representation sequencing methods are common alternatives for genotyping, but each of these methods has significant limitations associated with it.  

In this webinar, Charles Johnson, founder of the Texas A&M AgriLife Genomics and Bioinformatics Service, shares how his team developed a new approach, called AgSeq, to address these shortcomings.

AgSeq is a novel agriculture-focused genotyping pipeline that uses optimized laboratory processing, massive sample multiplexing, and machine learning to obtain highly accurate genotype information from low-coverage sequencing data. The reduced cost of whole-genome sequencing afforded by AgSeq allows for a substantial increase in individuals genotyped per study. AgSeq is powered by optimized library prep, automation, and high-throughput sequencing coupled with a reduction in the amount of data needed per individual. Data from individual samples is used to accurately impute gaps resulting from reduced coverage, allowing for accurate genotyping of large populations for plant and animal studies.  

Sponsored by
Genome Webinar

Professor of Bioinformatics, Microbiology and Cell Science Department, University of Florida

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.
 
NGS is a powerful method for characterizing eukaryotic gene expression. While short-read transcriptome sequencing data is inexpensive, it has major shortcomings, including difficulty detecting isoforms and gene fusions, trouble discriminating paralogous sequences, and difficulties in phasing alleles. Long-read sequencing such as PacBio Iso-Seq, meanwhile, offers long reads but at increased cost, higher error rates, and reduced quantification abilities.
 
Another approach, LoopSeq synthetic long-read sequencing technology from Loop Genomics, uses unique molecular identifiers to generate synthetic long reads on short-read Illumina sequencing instruments and no additional hardware. This method offers a promising option for human transcriptome sequencing by providing full-length mRNA sequencing coupled with UMI-based transcript counting for gene expression quantification.
 
In this webinar, Ana Conesa, Professor of Bioinformatics at the University of Florida, discusses a comparison study of short-read Illumina transcriptome sequencing and LoopSeq Transcriptome sequencing data for human transcriptome studies.

This is the second Loop Genomics GenomeWebinar on the topic of long-read versus short-read sequencing approaches. The first, which compared these methods in the context of microbiome sequencing, is available on demand here.

Sponsored by
Genome Webinar

Director of Research and Clinical Trials, Tricore Reference Laboratories

This webinar discusses how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Acute respiratory tract infections are caused by a wide range of viral and bacterial pathogens and may share similar clinical presentations that make it difficult for physicians to diagnose based on symptoms alone. Syndromic testing with multiplex molecular panels offers clinical labs a way to quickly distinguish between a broad array of respiratory pathogens.

Join Dr. Steve Young of Tricore Reference Laboratories as he presents a new technology for multiplexed respiratory testing in acutely ill patients. He shares data demonstrating the capabilities of syndromic respiratory testing as well as his impressions on the ease of doing comprehensive syndromic testing using the QIAstat-Dx solution*.

*coming soon

Sponsored by
Genome Webinar

Instructor of Pathology, Medical College of Wisconsin

Outbreaks of influenza infections are seasonal and can range from regional outbreaks to nationwide epidemics or even global pandemics. Mortality can range from 4 percent to 60 percent for at-risk patient populations, depending on the strain circulating in the environment. Rapid diagnostics can significantly improve patient care and control outbreaks by treating with antivirals and informing patients of proper precautions to reduce spread.

Over the past decade, there has been a large shift in diagnostic options, moving from cell culture to rapid point-of-care testing. Today, multiple CLIA-waved assays are approved and laboratory managers must decide which methods and assays are appropriate for their healthcare environment.

In this webinar, Dr. Faron will discuss current trends in influenza epidemiology, evaluate current FDA-cleared assays, and present the MCW team's findings on a recent time-of-motion study comparing three rapid influenza assays. Overall, these data should aid healthcare providers to improve and implement rapid influenza testing.

Pages